Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective

http://hdl.handle.net/10400.1/16569

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
16569.pdf		19.93 KB	Adobe PDF	Download

Authors

De Mello, Ramon Andrade

Castelo-Branco, Pedro

De Almeida Zia, Victor Andre

Pozza, Daniel Humberto

Tadokoro, Hakaru

URI

http://hdl.handle.net/10400.1/16569

Publisher

American Society of Clinical Oncology

Collections

FCB2-Artigos (em revistas ou actas indexadas)

CC License